1Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah; and.
2Department of Neurosurgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
J Neurosurg. 2020 Feb 1;132(2):380-387. doi: 10.3171/2018.10.JNS181480. Epub 2019 Feb 15.
Cavernous sinus meningiomas are complex tumors that offer a perpetual challenge to skull base surgeons. The senior author has employed a management strategy for these lesions aimed at maximizing tumor control while minimizing neurological morbidity. This approach emphasizes combining "safe" tumor resection and direct decompression of the roof and lateral wall of the cavernous sinus as well as the optic nerve. Here, the authors review their experience with the application of this technique for the management of cavernous sinus meningiomas over the past 15 years.
A retrospective analysis was performed for patients with cavernous sinus meningiomas treated over a 15-year period (2002-2017) with this approach. Patient outcomes, including cranial nerve function, tumor control, and surgical complications were recorded.
The authors identified 50 patients who underwent subtotal resection via frontotemporal craniotomy concurrently with decompression of the cavernous sinus and ipsilateral optic nerve. Of these, 25 (50%) underwent adjuvant radiation to the remaining tumor within the cavernous sinus. Patients most commonly presented with a cranial nerve (CN) palsy involving CN III-VI (70%), a visual deficit (62%), headaches (52%), or proptosis (44%). Thirty-five patients had cranial nerve deficits preoperatively. In 52% of these cases, the neuropathy improved postoperatively; it remained stable in 46%; and it worsened in only 2%. Similarly, 97% of preoperative visual deficits either improved or were stable postoperatively. Notably, 12 new cranial nerve deficits occurred postoperatively in 10 patients. Of these, half were transient and ultimately resolved. Finally, radiographic recurrence was noted in 5 patients (10%), with a median time to recurrence of 4.6 years.
The treatment of cavernous sinus meningiomas using surgical decompression with or without adjuvant radiation is an effective oncological strategy, achieving excellent tumor control rates with low risk of neurological morbidity.
海绵窦脑膜瘤是一类复杂的肿瘤,给颅底外科医生带来了持续的挑战。资深作者采用了一种针对这些病变的治疗策略,旨在最大限度地控制肿瘤,同时将神经功能损伤的风险降到最低。该方法强调结合“安全”的肿瘤切除和海绵窦的穹窿和外侧壁以及视神经的直接减压。在此,作者回顾了过去 15 年来应用该技术治疗海绵窦脑膜瘤的经验。
对过去 15 年(2002-2017 年)采用该方法治疗的海绵窦脑膜瘤患者进行回顾性分析。记录患者的转归,包括颅神经功能、肿瘤控制和手术并发症。
作者确定了 50 例通过额颞开颅术行次全切除术同时行海绵窦和同侧视神经减压的患者。其中 25 例(50%)在海绵窦内残留肿瘤接受辅助放疗。患者最常见的表现为颅神经(CN)III-VI 麻痹(70%)、视力减退(62%)、头痛(52%)或眼球突出(44%)。35 例患者术前存在颅神经缺损。在这些病例中,52%的神经病变术后改善;46%稳定;只有 2%恶化。同样,97%的术前视力减退术后改善或稳定。值得注意的是,10 例患者术后出现 12 例新的颅神经缺损,其中一半为一过性,最终缓解。最后,5 例(10%)患者出现影像学复发,复发的中位时间为 4.6 年。
采用手术减压联合或不联合辅助放疗治疗海绵窦脑膜瘤是一种有效的肿瘤治疗策略,可实现较高的肿瘤控制率,同时神经功能损伤的风险较低。